How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.com18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
Description:
This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis after SRS.
Sponsor:
Baptist Health South Florida
Phase:
Phase 1
Contacts:
Rupesh Kotecha, M.D. (PRINCIPAL_INVESTIGATOR) Rupesh Kotecha, M.D. (CONTACT)rupeshk@baptisthealth.net
(786) 596-2000
Kristy Reyes (CONTACT)kristina.reyes@baptisthealth.net
(786) 596-2000
Government Study Link:
NCT06048094 - Click here to see study onClinicalTrials.gov
fluciclovine
Isotope(s):
FLUORINE-18
Radioisotope: F-18
Theranostic Role: PET Imaging
T1/2 (Half-Life): 1.8 Hours
Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
Energy: Eβ+ 635 keV
Range: N/A
Decay Daughters: O18 (Stable)
Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
Target(s):
- Amino Acid Transport
Ligand Class: Small Molecules
Inclusion
- Diagnosis of cancer with radiographic finding of brain metastasis
- Planned treatment with SRS as per the treating physician team
- Any number of brain metastasis, with all lesions ≤ 2 cm in maximum dimension
- Individuals of reproductive potential need to employ two highly effective and acceptable forms of contraception for at least 4 weeks prior to screening and agree to use such a method during study participation up to an additional 1 week following the last 18F-fluciclovine PET
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Exclusion
- Prior whole-brain radiation therapy
- Radiographic evidence of leptomeningeal disease
Share your feedback
Help us improve your experience